2022-2088 is the forecast period in the market report.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the global peptide antibiotics market. In addition, complete analysis of changes on the global peptide antibiotics market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 pandemic can impact health care, procedures and regulations.
The global peptide antibiotics market is driven by the increasing incidence of infectious diseases. It is one of the major factors driving the growth of the peptide antibiotics market. Rising prevalence of various types of cancer and rising incidence of chronic pain are further estimated to drive the growth rate of the peptide antibiotics market. The growing incidence of antimicrobial resistance is also expected to provide profitable growth opportunities for the peptide antibiotic market. For example, according to the 2019 CDC Report on Threats to Antibiotic Resistance, in the United States 2.8 million cases of antimicrobial resistance are recorded annually in the United States with approximately 35,000 deaths per year. Additionally, CDC implements funding activities through CDC's Antimicrobial Resistance Initiative which supports more than 50 state health departments and several local health departments. CDC has also partnered with state and local health departments, federal agencies, and the private sector to reduce the threat of antimicrobial resistance. This is anticipated to be a key driving factor for growth of the market over the projection period.
The peptide antibiotics market is expected to present growth opportunities owing to the rising incidence of bloodstream infections associated with central lines. According to the Australian Institute of Health and Welfare, 700 Australian public hospitals reported 1,428 cases of Staphylococcus aureus bloodstream infections between 2019 and 2020. Of these, most infections were Staphylococcus aureus infections susceptible to methicillin. All types of blood infections are serious infections and can lead to long hospital stays. Hence, increasing prevalence of blood infections is expected to support the market growth over the forecast period.
The market has major restraining factor like several side effects regarding the long term use of the peptide antibiotics. Besides, lack of awareness regarding the high use of antibiotics is another factor which is expected to restrain the market growth over the forecast period.
The Covid-19 pandemic hampered the growth of market to major extent which has created a major challenges for the market growth. Also, complicated manufacturing procedure of peptide antibiotic sterile injectable drugs and lack of skilled work force for sterile drug manufacturing is expected to be major hampering for the market growth over the forecast the period.
The report provides in-depth analysis of global peptide antibiotics market, market size, and compound annual growth rate (CAGR) for the forecast period of 2022-2028, considering 2021 as the base year. With increasing demand for various peptide antibiotics in various applications like infectious diseases and cancer has led the increasing demand for market and is expected to witness the growth at a specific CAGR from 2022-2028.
The global peptide antibiotics market comprises of different market segment like product type, route of administration, disease, distribution channel and geography.
By product type, the Peptide Antibiotics includes key segment of
The non-ribosomal synthesized peptide antibiotics segment is expected to dominate the market over the forecast period. The growth of non-ribosomal synthesized peptide antibiotics is attributed to the growing demand for non-ribosomal synthesized antibiotics and the increasing availability of non-ribosomal synthesized antibiotics. There are several non-ribosomal synthesized antibiotics that are available in the peptide antibiotics market for various applications. Several structural features underlie their essential role in pharmaceutical chemistry. This includes, the rigidity of macrocycles facilitates target binding, backbone N-methylations enhance membrane permeability, and d- or ?-amino acids contribute proteolytic resistance. These antibiotics can be utilized in the treatment and mitigation of various infectious diseases. For example, bleomycin is used in the treatment of squamous cell carcinoma, testicular carcinoma, and lymphoma.
By route of administration, the Peptide Antibiotics market is segmented into
The injectable route is anticipated to lead the market gaining majority of the market share in 2021 and is expected to maintain its dominance over the estimated time period. The growth of the injectable segment is attributed to factors such as the availability of a large number of peptide antibiotics in injectable form. Also the high efficiency and better bioavailability of injectable peptide antibiotics is a key element which is expected to drive the growth of the market over the forecast period. Injectable provide high onset of action, better bioavailability and therapeutic efficacy. Therefore, the injectable are preferred over other route of administration. Oral is the most conventional and convenient route of administration and is expected to have significant growth over the forecast period.
By disease, the Peptide Antibiotics market is segmented into
The skin infection segment is likely to dominate the market during the forecast period. The growth of the skin infections segment is fuelled by the increasing prevalence of skin infections such as cellulitis, impetigo, boils, carbuncles and others, and the wide availability of drug products which are available to treat bacterial skin infections. However, the bloodstream infections segment is expected to experience the fastest growth during the forecast period. The growth of the segment is fuelled by the growing number of bloodstream infections, growing awareness of bloodstream infections, and the availability of a robust portfolio of bloodstream infection management drug products.
The Peptide Antibiotics market has distribution channel like
The hospital pharmacies segment is expected to find increasing demand in the market over the forecast period. The growth of the hospital pharmacy segment is fuelled by the increasing prevalence of bloodstream infections, nosocomial infections and long-term hospitalizations. The retail pharmacy segment is expected to register the fastest growth rate during the forecast period. Increase in prescriptions of peptide antibiotics due to various types of bacterial skin infections, eye infections is a major factor which is expected to propel the growth of retail pharmacy segment. The online pharmacy segment is expected to record a significant growth rate during the forecast period due to the increasing penetration of pharmacies in developed regions such as North America and Europe. Additionally, the growth of the number of online pharmacies in emerging economies like India and China is expected to stimulate the growth of this sector in the coming years.
The global Peptide Antibiotics market is studied for the following region
North America is expected to lead the peptide antibiotics market over the forecast period. North America is anticipated to witness increasing demand for peptide antibiotics owing to presence to well established market players and also various important initiatives introduced by public sector as well as private sector in the healthcare field. Moreover, growing demand for antibiotics in this region and increasing R&D activities in the region are expected to propel the industry during the forecast period. Asia-Pacific is expected to be the fastest growing region during the forecast period due to factors such as increasing prevalence of various infectious diseases, rise in geriatric population and increasing awareness patients regarding their health. Also, presence of developed economies like China, India and Japan are further contributing healthy growth in the market. Also, Europe is anticipated to have significant growth at specific growth rate.
The competitive landscape analysis of peptide antibiotics market is majorly focused on expanding the global growth of peptide antibiotics with new product innovation, business expansion, increasing presence of range of manufacturer operating in peptide antibiotics has led the growing demand for the market. Besides, the market offers range of drug products in different applications like infectious diseases and cancer are present to fulfil the required demand of consumer which is further contributing healthy growth in the market.
The key players studied in market are
July 2022: Boehringer Ingelheim, Evotec SE, and bioMérieux had announced that they had created a joint venture for making next generation of antimicrobials for fight against antimicrobial resistance.
January 2021: Aurinia Pharmaceuticals Inc. had announced that the U.S. Food and Drug Administration (FDA) has approved its drug LUPKYNISTM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN). LUPKYNIS is the first FDA-approved oral therapy for LN. LN causes irreversible kidney damage and significantly increases the risk of kidney failure, cardiac events, and death. It is one of the most serious and common complications of the autoimmune disease systemic lupus erythematosus (SLE).
Sizing for Year:||2019-2028|
Route of Administration
Players and its Competitors:|
Pfizer Inc. (US)
Merck & Co., Inc. (US)
AbbVie Inc (US)
Novartis AG (Switzerland)
GSK Group of Companies (UK)
Sandoz International GmbH (Germany)
Dr. Reddy’s Laboratories Ltd (India)
Xellia Pharmaceuticals (Denmark)
Teva Pharmaceutical Industries Ltd. (Israel)
Allergan Plc (Ireland)
AuroMedics Pharma LLC (US)
Cumberland Pharmaceuticals Inc (US)
Theravance Biopharma (Cayman Islands)
Pacgen Life Science Corporation (Canada)Phosphagenics Limited (Australia)
What would be forecast period in the market report?
2022-2088 is the forecast period in the market report.
What are the drivers for Peptide Antibiotics market?
The key driving factors of the market are the increasing incidences of central line associated blood stream infections and rising incidences of antimicrobial resistance among the general population.
Which is the leading distribution channel segment for Peptide Antibiotics market?
The hospital pharmacy segment has accounted the major market share, and is expected to witness the growth at highest pace during the forecast period.
Which region is gaining majority of market share during the forecast period (2021-2028)?
North America is expected to gain major market share during the forecast period (2021-2028).